AB Science SA · EURONEXT:AB

AB Science SA — Corporate Update (February 2022)

27 slides from AB Science SA's corporate update, Feb 28, 2022

  1. Slide 1: AB Science Webconference

    AB Science Webconference 28 February 2022

  2. Slide 2: Disclaimer

    Disclaimer This presentation, together with the material set forth herein, does not constitute an offer of securities for sale nor the solicitation of an offer to purchase securities in any jurisdiction. Distribution of such presentation in certain jurisdiction may constitute a breach of applicable

  3. Slide 3: Masitinib filing in the treatment of ALS in Canada under the NOC/c procedure

    Masitinib filing in the treatment of ALS in Canada under the NOC/c procedure

  4. Slide 4: Notice of Compliance with Conditions (NOC/c) policy criteria

    Notice of Compliance with Conditions (NOC/c) policy criteria  Market authorization under the NOC/c (Notice of Compliance with Conditions) policy allows Health Canada to provide earlier market access to potentially life-saving drugs  NOC/c status eligibility is restricted to:  New drug therapies i

  5. Slide 5: Health Canada pre-assessment concluded masitinib fulfills criteria for filing under NOC/c

    The Health Canada pre-assessment concluded that masitinib fulfills the criteria for filing and advance consideration under the NOC/c policy  This pre-assessment was made based on a pre-submission package sent by AB Science including, efficacy data of study AB10015, long- term survival data (75 mont

  6. Slide 6: Final decision of Health Canada is expected by the end of 2022

    Final decision of Health Canada is expected by the end of 2022 Notice of Non- Compliance Sponsor must Issuance of the Submission must Target of 200 Notice of respond on the NOC under the NOC/c eligibilty be filed within 60 days to review Compliance with conditions within NOC/c policy in days the app

  7. Slide 7: Market Access activities in parallel to registration process

    AB Science will perform Market Access activities in parallel to registration process and will be able to supply ALS Canadian patients immediately Canadian market access Supply of Canadian ALS patients Up to 12 months process, to be performed in parallel to registration process Safety / Health Canada

  8. Slide 8: Stand-alone commercialization strategy in Canada

    So far, AB Science prepares a stand-alone commercialization strategy in Canada  The number of ALS centers is limited in Canada (below 20)  ALS centers are mainly located in 11 cities  An in-house salesforce should be sufficient to service ALS centers in Canada Edmonton Vancouver Calgary Saskatoon

  9. Slide 9: Regulatory status with FDA and EMA

    Regulatory status with FDA and EMA  Following Health Canada decision, AB Science intends to discuss/rediscuss  Conditional approval with EMA  Accelerated approval with FDA  The discussion will be based on:  Efficacy data of study AB10015, with new ex-post analyses  Long-term survival data (75

  10. Slide 10: Update on clinical program across indications

    Update on clinical program across indications

  11. Slide 11: Masitinib - Amyotrophic Lateral Sclerosis (ALS)

    Update on Masitinib - Amyotrophic Lateral Sclerosis (ALS) Confirmatory Phase 3 study Market and competition  Study status: Actively recruiting  Competitive landscape:  Primary endpoint: Change in the ALSFRS-R score  Registered drugs : riluzole, edaravone (IV)  Enrolment: 550 patients  Drugs in

  12. Slide 12: Long-term survival follow-up showed +25 months survival benefit in ALS

    In ALS, long-term survival follow-up showed a significant survival benefit of +25 months when treatment was initiated early + 25 months in median Overall Survival in patients with moderate ALS Kaplan–Meier survival curves from masitinib study AB10015 long-term survival analysis progressors - Masitin

  13. Slide 13: Masitinib - Progressive forms of Multiple Sclerosis

    Update on Masitinib - Progressive forms of Multiple Sclerosis Confirmatory Phase 3 study Market and competition  Study status: Authorized in France and Sweden (announced  Competitive landscape: publicly), recruitment to start imminently  Registered drugs : Ocrevus (Roche/Genentech)  Primary endp

  14. Slide 14: Unmet need with no approved drugs for non-active SPMS

    There is a tremendous unmet need, with no approved drugs for non-active SPMS and only one for PPMS Masitinib Positioning Label Manufacturer Non-active First approved Primary Progressive Active Secondary Relapsing Secondary MS Progressive MS Remitting MS Progressive MS* Distribution of patients 15% 3

  15. Slide 15: Phase 2B/3 benefit on disability progression with masitinib

    Phase 2B/3 demonstrated significant benefit on disability progression with masitinib 4.5 mg/kg/day Significant reduction in change in EDSS (Primary Endpoint) 37% risk reduction in confirmed EDSS progression (3 months) 0.2 P=0.0256 P=0.1585 LSM Change 0.1 0.0 0 12 24 36 48 60 72 84 96 Weeks in Treatm

  16. Slide 16: Masitinib - Alzheimer's Disease

    Update on Masitinib - Alzheimer’s Disease Confirmatory Phase 3 study Market and competition  Study status: In preparation, to be initiated in 2022  Competitive landscape: Aducanumab, but positioned on prodromal AD  Primary endpoint: ADAS-COG and ADCS-ADL change at week 24  Targeted patients:  E

  17. Slide 17: Masitinib positioned in mild and moderate dementia

    Masitinib is positioned in patients with mild and moderate dementia, which is different from other compounds MMSE Score Disease severity Aducanumab Masitinib (mini mental state examination) Prodromal > 25 Prodromal AD > 22 / > 24 Mild [21 – 25] Mild & Moderate AD [ 12 – 25] Moderate [12 – 20] Severe

  18. Slide 18: Phase 2B/3 results presented at AAIC 2021

    The Phase 2B/3 study demonstrated a statistically significant reduction in cognitive impairment based on ADAS-COG and a significant improvement on daily activity based on ADCS-ADL with masitinib 4.5 mg/kg/day Significant effect on cognitive function after 24 weeks of treatment Change in ADAS-Cog - A

  19. Slide 19: Masitinib – Indolent Systemic Mastocytosis

    Update on Masitinib – Indolent Systemic Mastocytosis Confirmatory Phase 3 study Market and competition  Study status: Actively recruiting  Competitive landscape:  Aggressive systemic mastocytosis (not the positioning of masitinib)  Primary endpoint: Cumulative 75% response rate on baseline sever

  20. Slide 20: Masitinib – MCAS

    Update on Masitinib – MCAS Previous proof of efficacy in mastocytosis wild-type Phase 2 study in MCAS  Mast cell activation syndrome (MCAS) is a disease similar to  Study status: Authorized in France and US (announced publicly) mastocytosis but without the KIT D816V mutation  Primary endpoint: Co

  21. Slide 21: Three other confirmatory studies expected to be launched

    Masitinib - Three other confirmatory studies are expected to be launched sequentially following the initiation of the Alzheimer’s Disease study Next confirmatory studies to be launched Expected timeline for initiation Severe asthma uncontrolled by OCS or ICS Second half of 2022 Locally advanced panc

  22. Slide 22: Masitinib - Covid-19

    Update on Masitinib - Covid-19 AB21002 AB20001 Ambulatory or hospitalized patients with symptomatic mild and Hospitalized patients with moderate and severe COVID-19 moderate COVID-19  Study status: Actively recruiting  Study status: Actively recruiting  Primary endpoint: Change in clinical status

  23. Slide 23: AB8939 – Acute Myeloid Leukemia

    Update on AB8939 – Acute Myeloid Leukemia AB8939 differentiating factors Clinical study  New synthetic microtubule-destabilizing drug  Study status: Authorized in France, Canada and USA (announced publicly)  Able to overcome P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated drug resistance

  24. Slide 24: Update on financing and licensing strategy

    Update on financing and licensing strategy

  25. Slide 25: Financing commitments sufficient to launch masitinib in ALS in Canada

    With current financing commitments, AB Science has enough financial resources to launch commercialization of masitinib in ALS in Canada  25M€ commitment by historical shareholders, at the initiative of AB Science:  Financing of 7.5M€ by a historical investor on February 27, 2022, through the issua

  26. Slide 26: Update on licensing strategy

    Update on licensing strategy  The research of a licence is an objective of 2022 and is public  The execution of this search is confidential  An external financial service provider has been recruited to assist AB Science in this search  Any licence, will be assessed over the current stand-alone s

  27. Slide 27: Q&A

    Q&A

AB Science — Corporate Update (February 2022) on 6ix